Supreme Court agrees to hear Teva's Copaxone patent case

The Supreme Court will hear a case during its 2014-15 term, which starts in October, regarding Teva's patents on multiple sclerosis drug Copaxone. A reversal of a lower court's ruling would uphold the patents until September 2015, but competitors might introduce generic versions as early as next month. Experts say the case could have far-reaching effects on how patents are interpreted.

View Full Article in:

Bloomberg · New York Times (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ